HC Wainwright Reiterates Buy Rating for Perspective Therapeutics (NYSE:CATX)

HC Wainwright restated their buy rating on shares of Perspective Therapeutics (NYSE:CATX - Free Report) in a research report released on Wednesday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright also issued estimates for Perspective Therapeutics' FY2025 earnings at ($1.20) EPS.

CATX has been the topic of a number of other reports. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 17th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $14.56.

Remove Ads

Perspective Therapeutics Stock Up 1.2 %

CATX stock traded up $0.03 during trading on Wednesday, reaching $2.52. 933,336 shares of the stock were exchanged, compared to its average volume of 990,696. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05. The stock has a 50 day simple moving average of $3.03 and a 200-day simple moving average of $6.75.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its stake in shares of Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock valued at $5,788,000 after acquiring an additional 298,778 shares during the last quarter. State Street Corp raised its stake in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock valued at $64,014,000 after acquiring an additional 355,685 shares during the last quarter. FMR LLC raised its stake in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Perspective Therapeutics by 1,302.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock worth $635,000 after purchasing an additional 44,174 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.